mayo clinic glp 1 oral solution How GLP-1s affect older adults Mayo Clinic researchers have developed

Riddle MC, Cefalu WT, Evans PH, Gerstein HC, Nauck MA, Oh WK, Rothberg AE, le Roux CW, Rubino F, Schauer P, et al

SURPASS-4, a multicenter open-label RCT comparing treatment with tirzepatide and insulin glargine in T2D patients at increased CV risk for a median of 85 weeks, was the only study in the SURPASS program to include the change from baseline in eGFR and UACR and occurrence of eGFR decline of at least 40%, renal death, progression to end-stage kidney disease or new-onset MA among the prespecified analyses [48]

What Women at Josie Are Choosing At Josie, youll talk through the options with your provider based on your goals, health history, and preferences

doi: 10.14814/phy2.15462

Working with a knowledgeable healthcare professional, like a Midi clinician, can help you find a safe, appropriate planeven while new medications are still in development

Key Background Adverse side effects may also be causing a decline in GLP-1 use among people with type 2 diabetes